Suboptimal adherence to prescribed daily growth hormone regimen among medicaid beneficiaries in the United States

References

• Bao XL, Shi YF, Du YC, et al. Prevalence of growth hormone deficiency of children in Beijing. Chin Med J. 1992;105(5):401–405.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Feldkamp M, Harris D, et al. Utah growth study: growth standards and the prevalence of growth hormone deficiency. J Pediatr. 1994;125(1):29–35.
   PubMed Web of Science ®Google Scholar
• Rona RJ, Tanner JM. Aetiology of idiopathic growth hormone deficiency in England and Wales. Arch Dis Child. 1977;52(3):197–208.
   PubMed Web of Science ®Google Scholar
• Vimpani GV, Vimpani AF, Lidgard GP, et al. Prevalence of severe growth hormone deficiency. Br Med J. 1977;2(6084):427–430.
   PubMed Web of Science ®Google Scholar
• Komlos J, Breitfelder A. Differences in the physical growth of US-born black and white children and adolescents ages 2–19, born 1942–2002. Ann Hum Biol. 2008;35(1):11–21.
   PubMed Web of Science ®Google Scholar
• August GP, Lippe BM, Blethen SL, et al. Growth hormone treatment in the United States: demographic and diagnostic features of 2331 children. J Pediatr. 1990;116(6):899–903.
   PubMedGoogle Scholar
• Grimberg A, Lindberg A, Wajnrajch M, et al. Racial/ethnic disparities in US pediatric growth hormone treatment. Horm Res Paediatr. 2018;90(2):102–108.
   PubMedGoogle Scholar
• Cutfield WS, Derraik JG, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLOS One. 2011;6(1):e16223.
   PubMed Web of Science ®Google Scholar
• Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93(2):147–148.
   PubMed Web of Science ®Google Scholar
• Aydın BK, Aycan Z, Sıklar Z, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract. 2014;20(1):46–51.
   PubMed Web of Science ®Google Scholar
• Jin J, Sklar GE, Min Sen Oh V, et al. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269–286.
   PubMedGoogle Scholar
• Loftus J, Yaworsky A, Roland CL, et al. Systematic review of patient experience with a less frequent injection schedule for growth hormone deficiency. Acad Manag Care Pharm. Virtual 2021.
   Google Scholar
• McNamara M, Turner-Bowker DM, Westhead H, et al. Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: a discrete choice experiment. Patient Prefer Adherence. 2020;14:781–793.
   PubMed Web of Science ®Google Scholar
• Loftus J, Miller BS, Parzynski CS, et al. Association of daily growth hormone injection adherence and height among children with growth hormone deficiency. Endocr Pract. 2022. DOI:https://doi.org/10.1016/j.eprac.2022.02.013
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Loftus J, Chen Y, Alvir JMJ, et al. Sub-optimal adherence with daily growth hormones increases with each year of treatment in a US commercial claims database. J Endocr Soc. 2021;5(Suppl_1):A686–A686.
   Google Scholar
• Kaplowitz P, Manjelievskaia J, Lopez-Gonzalez L, et al. Economic burden of growth hormone deficiency in a US pediatric population. JMCP. 2021;27(8):1118–1128.
   PubMed Web of Science ®Google Scholar
• Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14(2):143–154.
   PubMedGoogle Scholar
• Hester C, Park C, Chung J, et al. Medication adherence in children and adolescents with acne vulgaris in Medicaid: a retrospective study analysis. Pediatr Dermatol. 2016;33(1):49–55.
   PubMedGoogle Scholar
• Landon BE, Schneider EC, Normand SL, et al. Quality of care in Medicaid managed care and commercial health plans. JAMA. 2007;298(14):1674–1681.
   PubMedGoogle Scholar
• Thompson JW, Ryan KW, Pinidiya SD, et al. Quality of care for children in commercial and medicaid managed care. JAMA. 2003;290(11):1486–1493.
   PubMedGoogle Scholar
• Farfel A, Shalitin S, Morag N, et al. Long-term adherence to growth hormone therapy in a large health maintenance organization cohort. Growth Horm IGF Res. 2019;44:1–5.
   PubMed Web of Science ®Google Scholar
• Hughes IP, Choong C, Rath S, et al. Early cessation and non-response are important and possibly related problems in growth hormone therapy: an OZGROW analysis. Growth Horm IGF Res. 2016;29:63–70.
   PubMed Web of Science ®Google Scholar
• De Pedro S, Murillo M, Salinas I, et al. Variability in adherence to rhGH treatment: Socioeconomic causes and effect on children’s growth. Growth Horm IGF Res. 2016;26:32–35.
   PubMed Web of Science ®Google Scholar
• Haverkamp F, Gasteyger C. A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children. J Med Econ. 2011;14(4):448–457.
   PubMedGoogle Scholar
• González Briceño LG, Viaud M, Beltrand J, et al. Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone. J Clin Endocrinol Metab. 2019;104(6):2103–2111.
   PubMed Web of Science ®Google Scholar
• Sugar S, Peters C, De Lew N, et al. Medicaid churning and continuity of care: Evidence and policy considerations before and after the COVID-19 pandemic. US Department of Health and Human Services; 2021. Available from: https://aspe.hhs.gov/system/files/pdf/265366/medicaid-churning-ib.pdf
   Google Scholar